Study finds shorter radiation regimen safe, effective for men with advanced prostate cancer

January 25, 2021


A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center found shortening a traditional 45-day course of radiation to a five-day course delivered in larger doses is safe and as effective as conventional radiation for men with high-risk forms of prostate cancer.

The findings show the five-day regimen of stereotactic body radiotherapy, a form of external beam radiation therapy that uses a higher dose of radiation, had a four-year cure rate of 82%. Severe side effects were also rare. Around 2% experienced urinary issues and less than 1% had bowel side effects.


Building on previous UCLA research that provided significant evidence that a shortened regimen of radiation could be a viable treatment option for men with low- and intermediate-risk prostate cancer, researchers decided to broaden the study to see if a shorter course would a viable option for men with aggressive disease.


Researchers analyzed data from 344 men with high-risk prostate cancer who were enrolled in a clinical trial from seven institutions across the globe, including UCLA. Minimum follow-up was 24 months and the median follow-up was 49.5 months. This the largest dataset to date that looked at this type of treatment in men with more aggressive prostate cancers can help improve the overall quality of life for men with prostate cancer.


Conventional radiation, which requires daily visits for treatment, can be burdensome for many. Shortening radiation therapy from six-and-a-half weeks to five days is a significant advancement that can help improve the overall quality of life for men with prostate cancer.

The senior author of the study is Dr. Amar Kishan, assistant professor of radiation oncology at the David Geffen School of Medicine at UCLA and researcher at the UCLA Jonsson Comprehensive Cancer Center. The first author is Dr. Ritchell van Dams, a resident in the department of Radiation Oncology at the David Geffen School of Medicine at UCLA. A full list of authors is cited on the paper.


The study was published online in the International Journal of Radiation Oncology, Biology, Physics.


The work was supported by an ASTRO-PCF Young Investigator Award for Kishan.

University of California - Los Angeles Health Sciences

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to